Page last updated: 2024-11-13
azd4694
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AZD4694: an Abeta plaque neuroimaging PET radioligand; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 24896605 |
| CHEMBL ID | 2048308 |
| SCHEMBL ID | 1923062 |
| MeSH ID | M0550379 |
Synonyms (19)
| Synonym |
|---|
| CHEMBL2048308 |
| azd4694 |
| g5k506j69e , |
| unii-g5k506j69e |
| 2-(2-fluoro-6-methylaminopyridin-3-yl)benzofuran-5-ol |
| 1054629-49-0 |
| azd 4694 |
| azd-4694 |
| flutafuranol |
| 2-(2-fluoro-6-methylamino-pyridin-3-yl)-benzofuran-5-ol |
| MYNQXTDIPMCJCR-UHFFFAOYSA-N |
| SCHEMBL1923062 |
| bdbm50485310 |
| Q27278793 |
| EX-A5369 |
| HY-113938 |
| 2-[2-fluoro-6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol |
| CS-0064225 |
| AKOS040751827 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Here, we report the preparation and pharmacokinetic profile of its carbon-11 (t1/2 = 20." | ( Synthesis, radiolabeling, and in vivo pharmacokinetic evaluation of the amyloid beta radioligand [11C]AZD4694 in nonhuman primates. Amini, N; Bergman, L; Cselenyi, Z; Farde, L; Gulyas, B; Halldin, C; Johnström, P; Lindström-Böö, E; Nakao, R; Sandell, J; Schou, M; Sumic, A; Svensson, S; Varnäs, K, 2014) | 0.62 |
| "The advantageous pharmacokinetic profile and low nonspecific binding render [(11)C]AZD4694 a promising PET radioligand for imaging of amyloid beta in the human brain with PET." | ( Synthesis, radiolabeling, and in vivo pharmacokinetic evaluation of the amyloid beta radioligand [11C]AZD4694 in nonhuman primates. Amini, N; Bergman, L; Cselenyi, Z; Farde, L; Gulyas, B; Halldin, C; Johnström, P; Lindström-Böö, E; Nakao, R; Sandell, J; Schou, M; Sumic, A; Svensson, S; Varnäs, K, 2014) | 0.84 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 (µMol) | 0.0240 | 0.0005 | 3.8895 | 10.0000 | AID671384 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (79)
Molecular Functions (13)
Ceullar Components (41)
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID671384 | Displacement of [3H]AZD2184 from human amyloid beta(1 to 40) | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13 | Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as ¹⁸F-PET imaging agents for β-amyloid plaques. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.69) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (11.11%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||